Higher Returns with Aurora Cannabis
By Rayk Riechmann
Investors want what they're on!
Aurora Cannabis Inc. (Nasdaq: ACB), a federally-licensed producer of medical and consumer cannabis, is attractively positioned as an early leader in global regulated markets. ACB leverages a best-in-class brand portfolio to grow and sell products across all major cannabis categories. And it's translating to results: the company just delivered a top-down beat on strengthening industry tailwinds and expanding global sales.
With a strong footprint in key medical cannabis markets in North America, Europe, and Australia, the company excels at meeting both patient and regulatory demands. This early adaptation of medical markets is already paying off with strong revenue growth and creates a first-mover advantage once these regions transform into recreational markets. Germany is close to creating a national legalized consumer market, and as other European nations follow suit, top-line growth could skyrocket.
ACB is strategically positioned to rapidly expand into new markets within Europe as regulatory liberalization continues. Notably, a local presence in these markets mostly shields ACB from tariff-related uncertainty.
Here's ACB's global presence in one glance: #1 in Canadian medical market share, #2 in Australia following the acquisition of MedReleaf Australia in 2024, #3 in Poland, and one of only three companies licensed to cultivate in Germany.
Since June 2021, ACB has introduced 24 new proprietary strains, which drive yield, potency, and cost-efficiency. Newly engineered next-gen cultivars appeal to consumers with increased consistency and save up to 30% in per-unit costs. Both are key differentiators in the consumer and medical market.
ACB's one-of-a-kind combination of regulatory expertise, brand architecture, and scientific innovation enables superior financial performance, as demonstrated in the top-down beat delivered in the latest quarter, driven mainly by a 51% increase in international medical cannabis revenue. The debt-free cannabis business has taken decisive steps to ensure profitable growth moving forward. By rightsizing its SG&A expenses and consolidating its manufacturing footprint, ACB delivered positive net-income for the second time in company history, as well as record adjusted EBITDA and FCF.
Our bullish outlook for 2025 is fueled by improved company profitability and favorable external forces. ACB currently trades at a NTM price/sales multiple of 0.96x – a big discount to its own 3-year mean multiple of 1.51x, indicating that the stock price has not caught up to recent developments and is due for a rerating. What's more, ACB trades at a significant discount to almost all peers on an Ebitda basis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Morning Bid: Oil pops, dollar drops
By Mike Dolan LONDON (Reuters) -What matters in U.S. and global markets today I'm excited to announce that I'm now part of Reuters Open Interest (ROI), an essential new source for data-driven, expert commentary on market and economic trends. You can find ROI on the Reuters website, and you can follow us on LinkedIn and X. Intro Not for the first time this year, markets are being hit by multiple crosscurrents. Today it's an oil price surge driven by Middle East tensions alongside surprisingly benign U.S. inflation readings. I discuss this and the rest of today's market news below. In today's column, I explore a surprising twist in the global dollar debate that could reshape how investors think about currency risk. I'll be off tomorrow so Morning Bid will take a day's holiday, but back to regular programming on Monday. Today's Market Minute * U.S. President Donald Trump said on Wednesday U.S. personnel were being moved out of the Middle East because "it could be a dangerous place", adding that the United States would not allow Iran to have a nuclear weapon. * U.S. consumer prices increased less than expected in May as cheaper gasoline partially offset higher rents, but inflation is expected to accelerate in the coming months on the back of the Trump administration's import tariffs. *An Air India plane bound for London with 242 people on board crashed minutes after taking off from India's western city of Ahmedabad on Thursday, the airline and police said, and India's federal health minister said that "many people" were killed. * U.S. trade negotiations have transitioned from their tumultuous opening act into a new chapter: the Slow Grind. It may be less turbulent than this past spring's drama, but no less worrying for investors. Oil pops, dollar drops With investors trying to read the runes of this week's 'framework' trade agreement between the U.S. and China on Wednesday, worries surfaced about the state of play in the Middle East after the U.S. announced that it was moving personnel out of the region ahead of talks with Iran over the latter's nuclear-related activity. Crude oil prices promptly jumped 4% and hit their highest in two months before giving up some of those gains earlier today. European travel stocks and auto makers fell more than 2% on Thursday on the jitters. Gold, however, was only marginally higher, and the dollar fell. While no specific reason was given for the U.S. personnel orders, the U.N. nuclear watchdog passed a resolution on Thursday formally declaring Iran in breach of its non-proliferation obligations for the first time in almost 20 years. Concern about Israeli threats to Iran's nuclear facilities inevitably ramped up. The prospect of higher energy prices at a time of tariff-related inflation concerns will certainly rankle. But so far at least, the Trump administration's import levies aren't putting much upward pressure on U.S. consumer prices, as May CPI came in below forecasts on Wednesday. Core annual producer price readings due out later today are expected to be steady. Despite this week's crude gains, year-on-year oil prices are still down more than 10%. And two-year U.S. 'breakeven' inflation rates in the inflation-protected Treasury market fell to their lowest of the year at 2.44%. Meanwhile, U.S. Treasury yields fell on a mix of soft inflation and robust demand at the 10-year auction on Wednesday. Some $22 billion of 30-year bonds are up for grabs later today, testing the recently shaky demand for long-duration debt. Federal Reserve expectations haven't shifted greatly, with two quarter-point interest rate cuts still priced by yearend. No move is expected before September, even though President Donald Trump once again called for an immediate full percentage point rate cut after the CPI report. The dollar remains under pressure however, raising more concern about the absence of its traditional 'safe haven' role at a time of rising geopolitical tensions. The dollar index fell to its lowest level since April, with the euro surging above $1.15 to within a whisker of its best levels since 2021. Sterling was a standout loser against the euro, falling to its weakest against the single currency in a month after a surprisingly sharp drop in April UK GDP. Stocks were slightly shaken by the whole picture, with the S&P500 ending in the red on the Middle East news on Wednesday and futures down almost half a percentage point ahead of Thursday's open. Chinese, Japanese and European bourses were all in the red on Thursday. Only South Korea's Kospi bucked the trend. The wider trade war picture remained uncertain despite the U.S.-China progress, with details still patchy as the negotiated deal in London awaited final approval. Trump on Wednesday said he was very happy with the trade deal, as it restored a fragile truce between the two biggest economies, claiming China agreed to free up rare earth supplies in exchange for the U.S. allowing Chinese students to attend U.S. colleges. But he also insisted: "We are getting a total of 55% tariffs, China is getting 10%." White House officials said the 55% represents the sum of a baseline 10% "reciprocal" tariff Trump has imposed on goods imported from nearly all U.S. trading partners, the 20% fentanyl-related tariffs, and pre-existing 25% levies on imports from China that were put in place during Trump's first term. Commerce Secretary Howard Lutnick said the 55% rate on Chinese imports is fixed and unalterable. Treasury Secretary Scott Bessent said the deal would not reduce U.S. export restrictions on high-end artificial intelligence chips. China on Thursday affirmed the trade deal, and a foreign ministry spokesperson said: "Now that a consensus has been reached, both sides should abide by it." But with less than four weeks to go before the expiration of the 90-day pause on U.S. tariffs worldwide, markets remain concerned about what will happen next month. Trump said on Wednesday he would be willing to extend a July 8 deadline for completing trade talks, but also said he did not believe that would be necessary, noting: "At a certain point, we're just going to send letters out ... saying, 'This is the deal. You can take it, or you can leave it.'" European Union talks, in particular, look unlikely to be concluded by then. Elsewhere, Boeing shares fell 6% pre-market after news that an Air India plane headed to London with 242 people on board crashed minutes after taking off from India's western city of Ahmedabad. Be sure to check out today's column, which looks at the weakening dollar and the debate about whether its decline is being driven by flight from U.S. assets at large or simply foreign investors hedging their dollar exposure. Chart of the day The UK may be seeing the downsides of publishing noisy monthly GDP readouts as opposed to quarterly updates. The April GDP report threw cold water on a relatively robust start to the year for the UK economy, showing a surprising 0.3% contraction during the month. However, it remains very unclear how much of the April loss will be durable through the second quarter. Either way, the data will put pressure on the Bank of England to step up monetary easing. Consequently, both sterling and UK government bond yields fell back after the GDP release. Today's events to watch * U.S. May producer price report (8:30 AM EDT), weekly jobless claims (8:30 AM EDT) * Federal Reserve issues Quarterly Financial Accounts of the United States (11:00 AM EDT) * U.S. Treasury auctions $22 billion of 30-year bonds * European Central Bank Vice President Luis de Guindos and ECB board member Isabel Schnabel both speak in Brussels * U.S. corporate earnings: Adobe Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias. Want to receive the Morning Bid in your inbox every weekday morning? Sign up for the newsletter here. (By Mike Dolan; Editing by Anna Szymanski and Gareth Jones) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
24 minutes ago
- Associated Press
Theralase Completes Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce the successful completion of its Annual General and Special Meeting ('AGSM'), which was held on Wednesday, June 11 th, 2025, at the Company's head office in Toronto, Ontario, Canada. Following shareholder approval on various resolutions and formal conclusion of the AGSM meeting, Theralase® hosted a virtual corporate presentation via Zoom to provide shareholders with an in-depth overview of the Company's strategic objectives and upcoming milestones for 2025 and 2026. The presentation highlighted current and planned clinical development programs focused on accelerating the commercialization of Theralase®'s innovative therapeutic technologies. For those unable to attend the live virtual session, an archived recording of the presentation can be accessed via the following link: Watch the AGSM Virtual Presentation here: AGSM Virtual Presentation Recording - Presented June 11th, 2025 Theralase® wishes to thank its shareholders and stakeholders for their ongoing support as the Company advances on its mission to commercialize safe and effective therapeutics to destroy various cancers, bacteria and viruses, with minimal impact on healthy tissue. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Associated Press
24 minutes ago
- Associated Press
The Lovesac Company Reports First Quarter Fiscal 2026 Financial Results
STAMFORD, Conn., June 12, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) ('Lovesac' or the 'Company'), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the first quarter of fiscal 2026, which ended May 4, 2025. Shawn Nelson, Chief Executive Officer, stated, 'Our first quarter performance was inline with our expectations to capitalize on secular initiatives to drive growth. Notably, we delivered topline growth and leveraged operating expenses as we have begun to reap the benefits of previous investments in core capabilities to bolster our infinity flywheel and accelerate our pace of product innovation. Our first quarter also reflected another period of market share gains despite persistent category headwinds and an evolving macroeconomic backdrop, thereby reinforcing our unique competitive advantages driven by our Designed for Life product platforms and efficient customer acquisition engines. As we enter the second quarter, we are thrilled to have launched our third Designed For Life Platform, EverCouch. This expansion into the armchair, loveseat and sofa category effectively doubles our total addressable market. While we remain cautious given the dynamic environment, we have high conviction in our long-term growth trajectory as we execute against our strategic roadmap and unlock the tremendous growth potential ahead.' Key Measures for the First Quarter of Fiscal 2026 Ending May 4, 2025: (Dollars in millions, except per share amounts. Dollar and percentage changes may not recalculate due to rounding.) 1 Adjusted EBITDA is a non-GAAP measure. See 'Non-GAAP Information' and 'Reconciliation of Non-GAAP Financial Measures' included in this press release. 1 Omni-channel Comparable Net Sales includes sales at all retail locations and online, open greater than 12 months (including remodels and relocations) and excludes closed stores. Highlights for the Quarter Ended May 4, 2025: Other Financial Highlights as of May 4, 2025: Outlook: The Company provides guidance of select information related to the Company's financial and operating performance, and such measures may differ from year to year. The projections are as of this date and the Company assumes no obligation to update or supplement this information. The Company currently expects the following for the full year of fiscal 2026: The Company currently expects the following for the second quarter of fiscal 2026: 1 Adjusted EBITDA is a non-GAAP measure. See 'Non-GAAP Information' and 'Reconciliation of Non-GAAP Financial Measures' included in this press release. Conference Call Information: A conference call to discuss the financial results for the first quarter ended May 4, 2025 is scheduled for today, June 12, 2025, at 8:30 a.m. Eastern Time. Investors and analysts interested in participating in the call are invited to dial (877) 407-3982 (international callers please dial (201) 493-6780) approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at A recorded replay of the conference call will be available within two hours of the conclusion of the call and can be accessed online at for 90 days. About The Lovesac Company: Based in Stamford, Connecticut, The Lovesac Company (NASDAQ: LOVE) is a technology driven company that designs, manufactures and sells unique, high quality furniture derived through its proprietary Designed for Life approach which results in products that are built to last a lifetime and designed to evolve as customers' lives do. The current product offering is comprised of modular couches called Sactionals, the Sactionals Reclining seat, premium foam beanbag chairs called Sacs, the Pillowsac™ Accent Chair, an immersive surround sound home theater system called StealthTech, and an innovative sofa seating solution called EverCouch™. As a recipient of Repreve's 7th Annual Champions of Sustainability Award, responsible production and innovation are at the center of the brand's design philosophy with products protected by a robust portfolio of utility patents. Products are marketed and sold primarily online directly at supported by a physical retail presence in the form of Lovesac branded showrooms, as well as through shop-in-shops and pop-up-shops with third party retailers. LOVESAC, DESIGNED FOR LIFE, SACTIONALS, SAC, STEALTHTECH, and THE WORLD'S MOST ADAPTABLE COUCH are trademarks of The Lovesac Company and are Registered in the U.S. Patent and Trademark Office. Non-GAAP Information: Adjusted EBITDA is defined as a non-GAAP financial measure by the Securities and Exchange Commission (the 'SEC') that is a supplemental measure of financial performance not required by, or presented in accordance with, GAAP. We define 'Adjusted EBITDA' as earnings before interest, taxes, depreciation and amortization, adjusted for the impact of certain non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include management fees, equity-based compensation expense, write-offs of property and equipment, deferred rent, financing expenses and certain other charges and gains that we do not believe reflect our underlying business performance. We have reconciled this non-GAAP financial measure with the most directly comparable GAAP financial measure within the schedules attached hereto. Statements regarding our expectations as to fiscal 2026 Adjusted EBITDA do not include certain charges and costs. These items include equity-based compensation expense and certain other charges and gains that we do not believe reflect our underlying business performance. We are not able to provide a reconciliation of our non-GAAP financial guidance to the corresponding GAAP measures without unreasonable effort because of the uncertainty and variability of the nature and amount of these future charges and costs. This is due to the inherent difficulty of forecasting the timing of certain events that have not yet occurred and are out of the Company's control. We believe that these non-GAAP financial measures not only provide its management with comparable financial data for internal financial analysis but also provide meaningful supplemental information to investors. Specifically, these non-GAAP financial measures allow investors to better understand the performance of our business, facilitate a more meaningful comparison of our actual results on a period-over-period basis and provide for a more complete understanding of factors and trends affecting our business. We have provided this information as a means to evaluate the results of our ongoing operations alongside GAAP measures such as gross profit, operating income (loss) and net income (loss). Other companies in our industry may calculate these items differently than we do. These non-GAAP measures should not be considered as a substitute for the most directly comparable financial measures prepared in accordance with GAAP, such as net income (loss) or net income (loss) per share as a measure of financial performance, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Non-GAAP financial measures have limitations as analytical tools, and investors should not consider them in isolation or as a substitute for analysis of the Company's results as reported under GAAP. Cautionary Statement Concerning Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other legal authority. Forward-looking statements can be identified by words such as 'may,' 'continue(s),' 'believe,' 'anticipate,' 'could,' 'should,' 'intend,' 'plan,' 'will,' 'aim(s),' 'can,' 'would,' 'expect(s),' 'expectation(s),' 'estimate(s),' 'project(s),' 'projections,' 'forecast(s)', 'positioned,' 'approximately,' 'potential,' 'goal,' 'pro forma,' 'strategy,' 'outlook' or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. All statements, other than statements of historical facts, included in this press release under the heading 'Outlook' and all statements regarding strategy, future operations and launch of new products, the pace and success of new products, future financial position or projections, future revenue, projected expenses, sustainability goals, prospects, plans and objectives of management are forward-looking statements. These statements are based on management's current expectations, beliefs and assumptions concerning the future of our business, anticipated events and trends, the economy and other future conditions. We may not actually achieve the plans, carry out the intentions or meet the expectations disclosed in the forward-looking statements and you should not rely on these forward-looking statements. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Among the key factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements include: business disruptions or other consequences of economic instability, recession, political instability, civil unrest, armed hostilities, natural and man-made disasters, pandemics or other public health crises, or other catastrophic events; the impact of changes or declines in consumer spending and increases in interest rates and inflation on our business, sales, results of operations and financial condition; cybersecurity and vulnerability to electronic break-ins and other similar disruptions; active pending or threatened litigation; our ability to manage and sustain our growth and profitability effectively, including in our ecommerce business, forecast our operating results, and manage inventory levels; our cash flows, changes in the market price of our common stock, global economic and market conditions and other considerations that could impact the specific timing, price and size of repurchases under our stock repurchase program or our ability to fund any stock repurchases; our ability to improve our products and develop and launch new products; our ability to successfully open and operate new showrooms; our ability to advance, implement or achieve the goals set forth in our ESG Report; our ability to realize the expected benefits of investments in our supply chain and infrastructure; disruption in our supply chain and dependence on foreign manufacturing and imports for our products; execution of our share repurchase program and its expected benefits for enhancing long-term shareholder value; our ability to acquire new customers and engage existing customers; reputational risk associated with increased use of social media; our ability to attract, develop and retain highly skilled associates and employees; system interruption or failures in our technology infrastructure needed to service our customers, process transactions and fulfill orders; any inability to implement and maintain effective internal control over financial reporting; unauthorized disclosure of sensitive or confidential information through breach of our computer system; the ability of third-party providers to continue uninterrupted service; the impact of changes in diplomatic and trade relations, as well as tariffs and the countermeasures and tariff mitigation initiatives; the regulatory environment in which we operate; our ability to maintain, grow and enforce our brand and intellectual property rights and avoid infringement or violation of the intellectual property rights of others; and our ability to compete and succeed in a highly competitive and evolving industry, as well as those risks and uncertainties disclosed under the sections entitled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our most recent Form 10-K and in our Form 10-Qs filed with the Securities and Exchange Commission, and similar disclosures in subsequent reports filed with the SEC, which are available on our investor relations website at and on the SEC website at Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Investor Relations Contact: Caitlin Churchill, ICR (203) 682-8200 [email protected]
